State Medicaid DUR Board Meeting - Revision 1
This is a Notice Revision
You are currently viewing a revision of a notice. This is a previous copy of a notice that has been published more recently. To view the current version of this notice, click here.
Please Note: Only the files that were associated to this version are included in the Download Attachments section. If that section does not display, all attachments were removed from this version of the notice.
General Information
- Government Type
- State Agency
- Entity
- Department of Health and Human Services (DHHS)
- Public Body
- Drug Utilization Review Board
Notice Information
- Notice Title
- State Medicaid DUR Board Meeting
- Notice Tags
- Medicaid, Pharmacies
- Notice Type(s)
- Meeting
- Event Start Date & Time
- March 13, 2025 07:15 AM
- Event End Date & Time
- March 13, 2025 08:30 AM
- Event Deadline Date & Time
- 03/13/25 08:30 AM
- Description/Agenda
- Drug Utilization Review Board Meeting Agenda Thursday, March 13, 2025 7:15 a.m. to 8:30 a.m. Google Meet joining info Video call link: meet.google.com/zue-rrqz-rpb Or dial: (US) +1 904-900-0180 PIN: 172 873 306# Persons who wish to address the DUR Board may contact Luis Moreno at lmoreno@utah.gov prior to the meeting, or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints. 1) Call to order - Luis Moreno, PharmD a) Welcome and Introductions - Luis Moreno, PharmD Housekeeping b) Review and Approval of Minutes 2) P&T Update - Ngan Huynh, PharmD 3) Review a) Aucatzyl (obecabtogene autoleucel) - Luis Moreno, PharmD i) Public Comment ii) Committee Discussion/Questions iii) Committee Action b) Breyanzi (lisocabtagene maraleucel) - Luis Moreno, PharmD i) Public Comment (1) Bristol Myers Squibb - Keith Huff, PharmD ii) Committee Discussion/Questions iii) Committee Action c) Kymriah (tisagenlecleucel) - Ngan Huynh, PharmD i) Public Comment (1) Novartis - Susie Moroney, PharmD ii) Committee Discussion/Questions iii) Committee Action d) Tecartus (brexucabtagene autoleucel) - Ngan Huynh, PharmD i) Public Comment ii) Committee Discussion/Questions iii) Committee Action 4) Next Meeting a) April 10, 2025 - Alyftrek & Other CFTR Modulators for Cystic Fibrosis Review 5) Adjourned
- Notice of Special Accommodations (ADA)
- In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Luis Moreno at lmoreno@utah.gov or (801) 538-6155.
- Notice of Electronic or Telephone Participation
- Video call link: meet.google.com/zue-rrqz-rpb Or dial: (US) +1 904-900-0180 PIN: 172 873 306#
Meeting Information
- Meeting Location
-
Video/Teleconferencing
Video/Teleconferencing, UT 84116
Show in Apple Maps Show in Google Maps - Contact Name
- Luis Moreno
- Contact Email
- lmoreno@utah.gov
- Contact Phone
- 801-538-6155
Notice Posting Details
- Notice Posted On
- February 26, 2025 05:00 PM
- Notice Last Edited On
- March 11, 2025 04:26 PM
- Deadline Date
- March 13, 2025 08:30 AM